Shannon M Conley Selected Research

Retinitis Pigmentosa (Pigmentary Retinopathy)

7/2023	Comparative study of PRPH2 D2 loop mutants reveals divergent disease mechanism in rods and cones.
10/2020	Retbindin: A riboflavin Binding Protein, Is Critical for Photoreceptor Homeostasis and Survival in Models of Retinal Degeneration.
1/2020	Novel molecular mechanisms for Prph2-associated pattern dystrophy.
10/2018	Oligomerization of Prph2 and Rom1 is essential for photoreceptor outer segment formation.
1/2017	Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa.
1/2016	The K153Del PRPH2 mutation differentially impacts photoreceptor structure and function.
1/2016	RDS Functional Domains and Dysfunction in Disease.
6/2015	Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype.
4/2010	Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa.
2/2010	Biochemical analysis of phenotypic diversity associated with mutations in codon 244 of the retinal degeneration slow gene.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shannon M Conley Research Topics

Disease

29	Retinal Degeneration 07/2023 - 01/2009
11	Retinitis Pigmentosa (Pigmentary Retinopathy) 07/2023 - 01/2009
8	Retinal Diseases 01/2021 - 01/2010
6	Macular Degeneration (Age-Related Maculopathy) 07/2023 - 02/2010
4	Hypertension (High Blood Pressure) 02/2024 - 01/2019
4	Blindness (Hysterical Blindness) 01/2022 - 09/2010
3	Cone-Rod Dystrophies 10/2020 - 01/2016
2	Hypertrophy 01/2024 - 01/2019
2	Cognitive Dysfunction 01/2024 - 01/2019
2	Inflammation (Inflammations) 09/2021 - 10/2004
2	congenital stationary Night blindness 01/2016 - 06/2015
2	Stargardt Disease 01/2016 - 09/2012
2	Glaucoma 04/2006 - 02/2004
1	Microvascular Rarefaction 01/2024
1	Atrophy 01/2022
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022
1	Scotoma (Scintillating Scotoma) 01/2022
1	Cochlear Diseases 01/2021
1	Phototoxic Dermatitis (Phototoxicity) 01/2020
1	Cerebral Hemorrhage 01/2019
1	Night Blindness (Nyctalopia) 01/2016
1	Hypoxia (Hypoxemia) 01/2016
1	Vitelliform Macular Dystrophy 04/2013
1	Hyperglycemia 01/2013
1	Microaneurysm 01/2013
1	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2013
1	Enhanced S-Cone Syndrome 01/2013
1	Ocular Hypertension (Glaucoma, Suspect) 04/2006
1	Starvation 10/2005

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2010
11	TetraspaninsIBA 07/2023 - 01/2010
10	PeripherinsIBA 10/2020 - 06/2014
7	Retinaldehyde (Retinal)IBA 01/2022 - 01/2013
6	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 10/2005
4	Rhodopsin (Visual Purple)IBA 10/2020 - 06/2015
3	Insulin-Like Growth Factor I (IGF-1)IBA 01/2024 - 01/2019
3	Glycoproteins (Glycoprotein)IBA 01/2016 - 01/2010
2	Angiotensin IIIBA 02/2024 - 01/2019
2	riboflavin-binding proteinIBA 10/2020 - 01/2020
2	Codon (Codons)IBA 01/2016 - 02/2010
2	AntioxidantsIBA 01/2016 - 10/2014
2	DisulfidesIBA 12/2010 - 03/2009
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2010 - 03/2009
2	SeleniumIBA 04/2006 - 02/2004
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 02/2024
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2024
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	tyrosine O-sulfateIBA 09/2021
1	Flavin-Adenine Dinucleotide (FAD)IBA 10/2020
1	Flavin Mononucleotide (FMN)IBA 10/2020
1	Riboflavin (Vitamin B2)FDA LinkGeneric 10/2020
1	FlavinsIBA 01/2020
1	Insulin (Novolin)FDA Link 01/2019
1	ElastinIBA 01/2019
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2018
1	LipidsIBA 01/2018
1	PolylysineIBA 01/2018
1	Cyclic Nucleotide-Gated Cation ChannelsIBA 03/2016
1	Free RadicalsIBA 01/2016
1	Catalytic RNA (Ribozymes)IBA 01/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016
1	SNARE Proteins (SNAREs)IBA 01/2015
1	yttria (yttrium oxide)IBA 10/2014
1	Retinal Pigments (Pigments, Visual)IBA 06/2014
1	Mutant Proteins (Protein, Mutant)IBA 12/2013
1	Cysteine (L-Cysteine)FDA Link 12/2010
1	OpsinsIBA 04/2010
1	Interleukin-10 (Interleukin 10)IBA 10/2004
1	Matrix Metalloproteinases (MMPs)IBA 02/2004

Therapy/Procedure

6	Therapeutics 01/2022 - 04/2010
1	Intravitreal Injections 09/2021